{"id":164261,"date":"2026-11-22T04:14:18","date_gmt":"2026-11-22T04:14:18","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/164261\/"},"modified":"2026-11-22T04:14:18","modified_gmt":"2026-11-22T04:14:18","slug":"novartis-stares-down-16-7b-post-2030-patent-cliff","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/164261\/","title":{"rendered":"Novartis stares down $16.7B post-2030 patent cliff"},"content":{"rendered":"<p>Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the early 2030s, as the upcoming U.S. generic entry for breast cancer blockbuster Kisqali prompted the Swiss drugmaker to trim its mid-term revenue outlook.<\/p>\n<p>Unveiled at an investor event in London on Thursday, Novartis <a href=\"https:\/\/www.novartis.com\/news\/media-releases\/novartis-projects-5-cc1-sales-cagr-through-2031-and-sustained-mid-single-digit-growth-over-long-term\" rel=\"nofollow noopener\" target=\"_blank\">projected<\/a> net sales to grow at a 5% compound annual rate in constant currencies between 2026 and 2031. That marks a slight step down from its prior guidance of 5% to 6% annual growth from 2025 through 2030.\u00a0<\/p>\n<p>Speaking on a press call ahead of Thursday\u2019s investor presentation, CEO Vas Narasimhan attributed the lower growth target to Kisqali\u2019s looming loss of U.S. market exclusivity in the second half of 2031, based on its patent settlement agreements.<\/p>\n<p>Kisqali is among three of Novartis\u2019 largest current growth pillars\u2014alongside Cosentyx and Kesimpta\u2014that are projected to plunge from $23.9 billion sales in 2030 to just $7.2 billion in 2035, creating a $16.7 billion hole in Novartis\u2019 top line. Kisqali is expected to suffer the biggest loss from $11 billion to $2.9 billion during the period.\u00a0<\/p>\n<p>Cosentyx, currently Novartis\u2019 top-selling drug, is expected to peak in 2027 before an Inflation Reduction Act-mandated price cut and the drug&#8217;s loss of exclusivity hit, Narasimhan explained during the investor event.\u00a0<\/p>\n<p>Even so, Narasimhan challenged Wall Street analysts\u2019 current consensus, which models Novartis\u2019 2035 sales at roughly $64 billion, leaving an approximately $20 billion gap to reach the mid-single-digit growth that Novartis maintained on Thursday through the mid-2030s. And the chief executive insisted that most of the post-2031 growth will be coming from Novartis\u2019 existing pipeline and brands, rather than M&amp;A.<\/p>\n<p>To build that longer-term momentum, Novartis is leaning on both newer commercial brands and promising pipeline candidates.\u00a0<\/p>\n<p>After it recently <a href=\"https:\/\/www.fiercepharma.com\/pharma\/novartis-ceo-unfazed-high-profile-clinical-failures-maintains-long-term-revenue-goal\" rel=\"nofollow noopener\" target=\"_blank\">raised<\/a> the peak sales target for BTK inhibitor Rhapsido to above $8 billion across urticaria and relapsing multiple sclerosis (Novartis plans to introduce a new brand name for the drug in neuroscience indications), Novartis on Thursday also dialed up its peak sales guidance for Kesimpta (from $6 billion to $8 billion), Scemblix and Leqvio (each from $4 billion to $5 billion).<\/p>\n<p>Narasimhan said the upgrades reflect commercial traction rather than new clinical data. These include Scemblix approaching 50% U.S. new-to-brand share in first-line chronic myeloid leukemia, while the PCSK9 drug Leqvio is getting a pre-filled syringe as Novartis accelerates work on an autoinjector.<\/p>\n<p>Behind in-market assets, Narasimhan outlined more than 20 new molecules in phase 3 and phase 2 trials, including nine with multibillion-dollar peak sales potential.<\/p>\n<p>He highlighted five core programs that are capable of generating the first $10 billion toward bridging the 2035 gap. Those include: Rhapsido, BAFF inhibitor and Sj\u00f6gren&#8217;s disease candidate ianalumab, BET inhibitor and myelofibrosis candidate pelabresib (for which Novartis is gearing up for a U.S. filing), Actinium-225 prostate cancer radioligand therapy Ac-PSMA-617, and Factor XI\/XIa inhibitor abelacimab (targeting a 2028 approval filing in atrial fibrillation).<\/p>\n<p>\u201cIf you\u2019re missing $10 billion in 2035, and you can\u2019t get there with the size of our pipeline, then your probabilities are wrong.\u201d Narasimhan said. \u201cThey\u2019re just wrong. It\u2019s just unlikely that that\u2019s going to be the case.\u201d<\/p>\n<p>He pointed to some other pipeline candidates, arguing that \u201cit just takes two or three of these to hit, and you get there.\u201d<\/p>\n<p>He stressed that the compound growth rate is not for each year but an average number through 2035.\u00a0<\/p>\n<p>While Novartis is proposing to keep its revenue trajectory based on its internal pipeline, the company <a href=\"https:\/\/www.fiercebiotech.com\/biotech\/novartis-ceo-argues-shareholders-happy-overall-calls-coins-act-adjustment\" rel=\"nofollow noopener\" target=\"_blank\">remains active <\/a>on the dealmaking front. But management suggested that most of the deals that Novartis strikes are simply too early-stage to move the needle for the midterm and would have \u201ca marginal impact\u201d for the 2031-2035 timeframe.<\/p>\n<p>\u201cThe vast majority of our deal activity is in exploratory to preclinical,\u201d Narasimhan said. \u201cMost of the deals we do and we plan to do remain in the sub-$2 billion space.\u201d<\/p>\n<p>\u201cWe selectively do larger deals, but we believe that having that strategy consistently over time can generate big winners,\u201d he added.<\/p>\n<p>In addition to growing the top line, Novartis also aims for its core operating income margin to return to above 40% by 2029.\u00a0<\/p>\n<p>Narasimhan noted that Novartis is evolving toward a 50-50-split between its U.S. and international businesses, which means lower profit margins compared with its Big Pharma peers with bigger U.S. contributions. He acknowledged that not having a mega-brand would weigh on the margin but argued that diversification matters.<\/p>\n<p>\u201cYou could argue from both a mission standpoint for Novartis, but also in terms of our profile,\u201d Narasimhan said. \u201cWe\u2019re more diversified. Diversify the risk, diversify as well in terms of pulling the margin down.\u201d<\/p>\n<p>By Novartis\u2019 count, the Swiss pharma will have the most $5 billion-plus brands in the industry by the end of the decade, which Narasimhan said is better than spreading them out into many $2 billion-plus products in terms of business efficiency.\u00a0<\/p>\n<p>\u201cWe do believe we can be in the 40s over time, but what we won\u2019t ever want to do is compromise on the R&amp;D investments,\u201d Narasimhan said. \u201cWe want to main that 20%-plus R&amp;D investment, and that has to be the core of the P&amp;L in the long run.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"Novartis is gearing up to defend its growth trajectory against a steep wave of patent expirations in the&hellip;\n","protected":false},"author":2,"featured_media":164262,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[19059,41939,625,14243,56067,206,44159,76050,2536,11213,9827],"class_list":["post-164261","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-cosentyx","tag-fierce-pharma-homepage","tag-financials","tag-kisqali","tag-leqvio","tag-novartis","tag-patent-cliff","tag-patent-losses","tag-pharma","tag-rhapsido","tag-vas-narasimhan"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/117658154826176656","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=164261"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/164261\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/164262"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=164261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=164261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=164261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}